EDITOR, The report of the working group on the management of neonatal respiratory distress syndrome states that 'normal' limits for blood gas variables cannot be stated, and appropriate levels of arterial oxygen saturation (Sao2 ) have not yet been agreed.' As a result they recommend that further research includes determining safe levels of Sao2 in infants with respiratory distress syndrome and chronic lung disease. Despite this area of uncertainty, they state that 'the recommended range for Pao2 [arterial oxygen tension] is 6-10 kPa and that acceptable levels for Sao2 of 85-93% have been proposed'. These ranges are stated without reference to reported normal values and may in fact be detrimental to an infant.
The fifth centile for levels of Sao2 in 'healthy' preterm infants without lung disease and either ready for discharge from the neonatal unit,2 or in the first week of life,3 are 95 7% and 95-5% respectively. These measurements were made with the Nelleor N100/N200 during quiet sleep and excluding the transient drops in Sao2 after normal apnoeic pauses. By definition, hypoxaemia is below these levels and should be corrected when treating respiratory failure.
In order to avoid hyperoxaemia (for which definitions vary) in preterm infants receiving mechanical ventilation, the upper limit of Sao2 must also be specified. we would recommend that baseline Sao2 is kept between 94 and 96% in preterm infants receiving additional inspired oxygen and monitored using the Nellcor pulse oximeter. In addition, and as the working group stresses, the monitoring of arterial line P02 values will remain essential to assess the effect of respiratory support and to be certain of avoiding hyperoxaemia.
Lower levels of Sao2 may be detrimental: firstly, preterm infants with a low baseline Sao2 desaturate further with apnoeic pauses than those who are adequately oxygenated.8
Secondly, hypoxaemia as a result of lung hypoxia increases both pulmonary vascular and bronchiolar smooth muscle tone.9 10 Such changes may prolong ventilatory and oxygen dependence, increase the risk for severe hypoxaemic episodes, and result in infants being treated with diuretics and bronchodilators. Inspired oxygen is a potent pulmonary vasodilator and may also prevent bronchoconstriction.9 10 We agree with the recommendation in appendix A that one of the most important steps forward here would be a randomised controlled trial looking at the levels of oxygenation that should be aimed for in treating neonates with respiratory distress syndrome. Such a study should include information concerning retinopathy as well as major outcome variables, such as death, chronic lung disease, the duration of inspired oxygen, and levels of required ventilation. 
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